Neukio Biotherapeutics is a China-based biotechnology startup that was founded in 2021. The company focuses on the development of next-generation allogenic cell therapies via the iPSC-CAR-NK axis, emphasizing innovative immuno-oncology products. Recently, on 02 September 2022, Neukio Biotherapeutics secured a significant $50.00M Series A investment from a group of prominent investors, including Lilly Asia Ventures, IDG Capital, Sherpa Venture Capital, CD Capital, Kuanyu Private Equity, and Yahui Precision Medicine Fund.
Neukio Biotherapeutics
Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis.
Founded 2021
China
14 employees
Series A
Total: $90.00M
Biotechnology
China
14 employees
Series A
Total: $90.00M
Biotechnology
General Information
Get notified when Neukio Biotherapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Neukio Biotherapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
China Market
Biotechnology
About Neukio Biotherapeutics
Taxonomy: cell therapy, allogenic, iPSC, CAR-NK, immuno-oncology, innovation, oncology, immune system, therapy development, biotherapeutics
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | •••••• | 6 |
|
02 Sep 2022 |
| Angel Round | •••••• | 3 |
|
29 Jul 2021 |
Neukio Biotherapeutics Alternatives & Competitors
Neukio Biotherapeutics vs
JancsiTech
China
JancsiTech is a company focusing on intelligent radiation therapy and navigation.
Seed
6 employees
Health Care
Neukio Biotherapeutics vs
Neukio Biotherapeutics vs
EXUMA Biotech
United States
EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market cell & gene...
Series B
25 employees
Big Data, Biotechnology
FAQ About Neukio Biotherapeutics
Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis.
Neukio Biotherapeutics was founded in 2021.
Neukio Biotherapeutics is headquartered in China.
Neukio Biotherapeutics operates in the following industries: Biotechnology.
Neukio Biotherapeutics has approximately 14 employees.
Neukio Biotherapeutics has completed 2 funding rounds, raising a total of $90.00M. The latest funding stage is Series A.
Top alternatives and competitors to Neukio Biotherapeutics include JancsiTech, Hyperthermia Cancer Institute, EXUMA Biotech, Central Alabama Radiation Oncology, Astera Cancer Care. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neukio Biotherapeutics and JancsiTech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors Neukio Biotherapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
